ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OGN / options
XENE (37) AMLX (39) IRON (54) ACAD (49) ⌘ Pro Terminal →

Organon & Co. (OGN) Options Positioning, Max Pain & Unusual Sweeps

$13.84 +0.22% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.88

Organon & Co. (OGN) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (53.3% gross margin, 25% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $3.63B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Organon & Co. (NYSE: OGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $13.84 (+0.22% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, OGN ranks #76 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OGN compare to XENE and AMLX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGN carries a Roarable B- (70/100 RQD), trailing P/E of 19.4x, gross margin of 53.3%, and ROIC of 24.9%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OGN?
▼

Per OGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821825), Organon & Co. generated $6.22B in revenue (-2.9% YoY), $187.0M in net income, and $538.0M in free cash flow against $12.87B in total assets and $8.63B in total debt. Key quantitative strengths: Strong cash generator (53.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.88 (+0.28%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 8.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B-
025507510070
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk D
Cash (18)Whales (16)SEC (11)Macro (9)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
$17 Bull$15 Base$11 Bear
📬 FREE OGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGN)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY OGN SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 8.7% FCF Margin ($538.0M FCF) & 53.3% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (64.5) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$13.77-0.1% Next Q
Q2 (-2Q)
65
Grade C+$13.76-0.1% Next Q
Q3 (-1Q)
67
Grade B-$13.75+0.7% Next Q
Current
70
Grade B-$13.84+6.6% Hist 90D α
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the OGN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, OGN faces multiple-compression risk if 19.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.74) or 200D SMA ($11.57) invalidates the momentum regime and cuts Target Base ($14.59) toward Bear Floor ($11.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 70%NO 30%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±1.8%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (OGN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for OGN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating OGN & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on OGN
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.37%⚡ TESTING RESISTANCE
2026-11-03O $13.81H $13.84L $13.81C $13.84VOL 1.85M
RES: $13.86SUP: $13.76SMA50: $13.74SMA200: $11.57
$14.25$12.54$10.82$9.10$7.39RES $13.86SUP $13.76$13.842026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OGN Butterfly Map → + Track OGN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
12.8%/yr Implied 5Y Growth

vs. -2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGN)

Health Care Rank #76 of 1015 ⚔️ XENE vs OGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OGN vs. XENE, AMLX, IRON, ACAD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Organon & Co. (OGN) ranks #76 by composite RQD confidence (70/100, grade B-) and #188 by equity capitalization ($3.63B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OGN ACTIVE
Organon & Co.
B- 70/100 19.4x 53.3% 24.9% +0.22% $3.63B Benchmark Subject
XENE
Xenon Pharmaceuticals Inc.
D- 37/100 — — -35.0% -0.35% $3.62B /xene-vs-ogn →
AMLX
Amylyx Pharmaceuticals Inc.
D- 39/100 — — -35.0% +0.63% $3.62B /amlx-vs-ogn →
IRON
Disc Medicine Inc.
D+ 54/100 — — -27.5% -2.41% $3.59B /iron-vs-ogn →
ACAD
ACADIA Pharmaceuticals Inc.
D 49/100 9.1x 91.7% 7.9% -0.82% $3.55B /acad-vs-ogn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001821825 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Organon & Co. (OGN) reported GAAP revenue of $6.22B (-2.9% vs. FY2024 revenue of $6.40B , and -0.8% cumulative change since FY2023) , GAAP net income of $187.0M, operating cash flow of $700.0M, and free cash flow of $538.0M (-29.6% YoY). On the balance sheet, OGN closed FY2025 with $12.87B in total assets against $8.63B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.22B $187.0M $700.0M $538.0M $12.87B $8.63B
FY2024 (FY) 2024-12-31 $6.40B $864.0M $939.0M $764.0M $13.10B $8.86B
FY2023 (FY) 2023-12-31 $6.26B $1.02B $799.0M $799.0M — —

3. OGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Organon & Co. (NYSE: OGN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $13.84 (+0.22% 1D, market cap $3.63B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, OGN ranks #76 in composite RQD confidence.

How does OGN compare to XENE and AMLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGN carries a Roarable B- (70/100 RQD), trailing P/E of 19.4x, gross margin of 53.3%, and ROIC of 24.9%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OGN?

Per OGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821825), Organon & Co. generated $6.22B in revenue (-2.9% YoY), $187.0M in net income, and $538.0M in free cash flow against $12.87B in total assets and $8.63B in total debt. Key quantitative strengths: Strong cash generator (53.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OGN trading relative to its 50-day, 200-day, and 52-week technical levels?

OGN last traded at $13.84 (+0.22% on volume of 1,848,197 shares), positioning the stock +0.73% above its 50-day simple moving average ($13.74) and +19.62% above its 200-day simple moving average ($11.57). Across its 52-week range of $5.69 to $13.84, OGN sits at the 100.0% percentile with a 14-day RSI of 64.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($13.59 to $14.09).

Direct Sub-Reports: OGN RQD Cockpit OGN 12M Forecast OGN Earnings & Move OGN Dividends & DRIP OGN Insiders & 13F OGN Whale Options OGN Profit Sankey OGN News & Why
ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

OGN — Organon & Co.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Organon & Co. (OGN) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $13.84 (+0.22% 1D, market capitalization $3.63B).

  • Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 24.9%, gross margin of 53.3%, operating margin of —, and free cash flow yield of 14.83%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of 8.50x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Organon & Co. (OGN) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $6.22B for FY 2025. The supply chain is recorded as "NONE."

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Organon & Co. (OGN) reported $6.22B in annual revenue (up from $6.40B in FY2024, -2.9% YoY) and $187.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.26B revenue, $1.02B net income) through FY2025, OGN scaled operating cash flow to $700.0M and free cash flow to $538.0M, backed by $12.87B in total assets against $8.63B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B- • RQD 70/100): Strong cash generator (53.3% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $5.69 – $13.84 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 19.4x trailing P/E against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care classification.

  • Key Question #1: Can OGN sustain or expand its — operating margin and 24.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.22B and free cash flow of $538.0M, how will capital allocation balance growth reinvestment against $8.63B in total debt?
  • Key Question #3: How sensitive is OGN's 18.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Organon & Co. (OGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OGN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OGN Bull vs. Bear Conversation Board — What's Your Call at $13.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OGN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $17.30 (+25.0%)
📌 Pinned Debate

Per the RQD rating, the fundamental cash engine scores 18 of 20 on ROIC of 24.9% and an FCF yield of 14.83%.

Don't sleep on OGN's setup in Health Care. Per the RQD rating, the fundamental cash engine scores 18 of 20 on ROIC of 24.9% and an FCF yield of 14.83%.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (70/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

@ForensicBear Shorting a 16/20 institutional whale-flow stock at $13.84 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $11.07 (-20.0%)
Spot @ $13.84

Net income fell from $1.02B in FY 2023 to $187.0M in FY 2025 while debt stood at $8.63B.

I respect the product at Organon & Co., but the stock at $13.84 is a different story. Net income fell from $1.02B in FY 2023 to $187.0M in FY 2025 while debt stood at $8.63B.. FCF yield is 14.83% and RQD sits at 70/100 (B-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%